Intrinsic value of Immunogen - IMGN

Previous Close

$5.83

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$5.83

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of IMGN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  118
  120
  124
  127
  131
  135
  140
  145
  150
  156
  162
  169
  176
  183
  191
  199
  208
  217
  227
  238
  249
  260
  273
  286
  299
  314
  329
  344
  361
  379
Variable operating expenses, $m
  364
  372
  381
  392
  404
  417
  431
  447
  463
  481
  500
  520
  542
  565
  589
  615
  642
  671
  702
  734
  768
  804
  842
  882
  924
  968
  1,014
  1,063
  1,115
  1,169
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  364
  372
  381
  392
  404
  417
  431
  447
  463
  481
  500
  520
  542
  565
  589
  615
  642
  671
  702
  734
  768
  804
  842
  882
  924
  968
  1,014
  1,063
  1,115
  1,169
Operating income, $m
  -246
  -251
  -258
  -265
  -273
  -282
  -292
  -302
  -313
  -325
  -338
  -352
  -366
  -382
  -398
  -416
  -434
  -454
  -475
  -496
  -519
  -544
  -569
  -596
  -624
  -654
  -686
  -719
  -754
  -790
EBITDA, $m
  -242
  -248
  -254
  -261
  -269
  -278
  -287
  -297
  -308
  -320
  -333
  -346
  -361
  -376
  -392
  -409
  -428
  -447
  -467
  -489
  -511
  -535
  -560
  -587
  -615
  -644
  -675
  -708
  -742
  -778
Interest expense (income), $m
  0
  0
  -14
  -14
  -14
  -14
  -14
  -14
  -14
  -13
  -13
  -13
  -13
  -12
  -12
  -12
  -12
  -11
  -11
  -10
  -10
  -10
  -9
  -9
  -8
  -8
  -7
  -7
  -6
  -5
  -5
Earnings before tax, $m
  -246
  -237
  -243
  -251
  -259
  -268
  -278
  -288
  -300
  -312
  -325
  -339
  -354
  -370
  -387
  -404
  -423
  -443
  -464
  -486
  -510
  -534
  -560
  -588
  -617
  -647
  -679
  -713
  -748
  -786
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -246
  -237
  -243
  -251
  -259
  -268
  -278
  -288
  -300
  -312
  -325
  -339
  -354
  -370
  -387
  -404
  -423
  -443
  -464
  -486
  -510
  -534
  -560
  -588
  -617
  -647
  -679
  -713
  -748
  -786

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  85
  87
  90
  92
  95
  98
  101
  105
  109
  113
  117
  122
  127
  133
  138
  144
  151
  158
  165
  172
  180
  189
  198
  207
  217
  227
  238
  250
  262
  274
Adjusted assets (=assets-cash), $m
  85
  87
  90
  92
  95
  98
  101
  105
  109
  113
  117
  122
  127
  133
  138
  144
  151
  158
  165
  172
  180
  189
  198
  207
  217
  227
  238
  250
  262
  274
Revenue / Adjusted assets
  1.388
  1.379
  1.378
  1.380
  1.379
  1.378
  1.386
  1.381
  1.376
  1.381
  1.385
  1.385
  1.386
  1.376
  1.384
  1.382
  1.377
  1.373
  1.376
  1.384
  1.383
  1.376
  1.379
  1.382
  1.378
  1.383
  1.382
  1.376
  1.378
  1.383
Average production assets, $m
  19
  20
  20
  21
  21
  22
  23
  23
  24
  25
  26
  27
  28
  30
  31
  32
  34
  35
  37
  39
  40
  42
  44
  46
  48
  51
  53
  56
  59
  61
Working capital, $m
  -48
  -49
  -50
  -51
  -53
  -55
  -57
  -59
  -61
  -63
  -66
  -68
  -71
  -74
  -77
  -81
  -84
  -88
  -92
  -96
  -101
  -105
  -110
  -116
  -121
  -127
  -133
  -140
  -146
  -153
Total debt, $m
  -234
  -232
  -230
  -228
  -225
  -222
  -219
  -216
  -213
  -209
  -205
  -201
  -196
  -191
  -186
  -181
  -175
  -169
  -162
  -155
  -148
  -141
  -133
  -124
  -115
  -106
  -96
  -86
  -75
  -64
Total liabilities, $m
  77
  79
  81
  83
  85
  88
  91
  94
  98
  102
  106
  110
  114
  119
  124
  130
  136
  142
  148
  155
  162
  170
  178
  186
  195
  204
  214
  225
  236
  247
Total equity, $m
  9
  9
  9
  9
  9
  10
  10
  10
  11
  11
  12
  12
  13
  13
  14
  14
  15
  16
  16
  17
  18
  19
  20
  21
  22
  23
  24
  25
  26
  27
Total liabilities and equity, $m
  86
  88
  90
  92
  94
  98
  101
  104
  109
  113
  118
  122
  127
  132
  138
  144
  151
  158
  164
  172
  180
  189
  198
  207
  217
  227
  238
  250
  262
  274
Debt-to-equity ratio
  -27.390
  -26.570
  -25.680
  -24.730
  -23.740
  -22.720
  -21.670
  -20.620
  -19.560
  -18.500
  -17.450
  -16.420
  -15.410
  -14.420
  -13.450
  -12.510
  -11.590
  -10.700
  -9.850
  -9.020
  -8.220
  -7.450
  -6.710
  -6.000
  -5.320
  -4.670
  -4.040
  -3.440
  -2.870
  -2.320
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -246
  -237
  -243
  -251
  -259
  -268
  -278
  -288
  -300
  -312
  -325
  -339
  -354
  -370
  -387
  -404
  -423
  -443
  -464
  -486
  -510
  -534
  -560
  -588
  -617
  -647
  -679
  -713
  -748
  -786
Depreciation, amort., depletion, $m
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
  10
  10
  11
  11
  12
  12
Funds from operations, $m
  -242
  -233
  -239
  -247
  -255
  -264
  -273
  -284
  -295
  -307
  -320
  -334
  -348
  -364
  -380
  -398
  -416
  -436
  -457
  -479
  -502
  -526
  -552
  -579
  -607
  -637
  -669
  -702
  -737
  -773
Change in working capital, $m
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
Cash from operations, $m
  -241
  -232
  -238
  -245
  -253
  -262
  -271
  -282
  -293
  -305
  -317
  -331
  -345
  -361
  -377
  -394
  -413
  -432
  -453
  -474
  -497
  -521
  -547
  -573
  -602
  -631
  -662
  -695
  -730
  -766
Maintenance CAPEX, $m
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -8
  -9
  -9
  -10
  -10
  -11
  -11
  -12
New CAPEX, $m
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
Cash from investing activities, $m
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -7
  -9
  -9
  -9
  -10
  -10
  -10
  -11
  -11
  -12
  -12
  -14
  -14
  -15
Free cash flow, $m
  -245
  -236
  -243
  -250
  -258
  -267
  -277
  -287
  -298
  -310
  -323
  -337
  -352
  -368
  -384
  -402
  -421
  -440
  -461
  -483
  -507
  -531
  -557
  -584
  -613
  -643
  -675
  -709
  -744
  -781
Issuance/(repayment) of debt, $m
  -236
  2
  2
  2
  3
  3
  3
  3
  3
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
  7
  7
  8
  8
  8
  9
  9
  10
  10
  11
  11
Issuance/(repurchase) of shares, $m
  484
  237
  244
  251
  259
  268
  278
  289
  300
  312
  326
  340
  354
  370
  387
  405
  424
  444
  465
  487
  510
  535
  561
  589
  618
  648
  680
  714
  750
  787
Cash from financing (excl. dividends), $m  
  248
  239
  246
  253
  262
  271
  281
  292
  303
  316
  330
  344
  359
  375
  392
  410
  430
  450
  471
  494
  517
  543
  569
  597
  627
  657
  690
  724
  761
  798
Total cash flow (excl. dividends), $m
  3
  3
  3
  3
  4
  4
  5
  5
  5
  6
  6
  7
  7
  7
  8
  8
  9
  9
  10
  10
  11
  12
  12
  13
  14
  14
  15
  16
  17
  18
Retained Cash Flow (-), $m
  -484
  -237
  -244
  -251
  -259
  -268
  -278
  -289
  -300
  -312
  -326
  -340
  -354
  -370
  -387
  -405
  -424
  -444
  -465
  -487
  -510
  -535
  -561
  -589
  -618
  -648
  -680
  -714
  -750
  -787
Prev. year cash balance distribution, $m
  211
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -270
  -234
  -241
  -248
  -255
  -264
  -274
  -284
  -295
  -307
  -319
  -333
  -347
  -363
  -379
  -397
  -415
  -434
  -455
  -477
  -499
  -524
  -549
  -576
  -604
  -634
  -665
  -698
  -733
  -769
Discount rate, %
  5.60
  5.88
  6.17
  6.48
  6.81
  7.15
  7.50
  7.88
  8.27
  8.69
  9.12
  9.58
  10.06
  10.56
  11.09
  11.64
  12.22
  12.84
  13.48
  14.15
  14.86
  15.60
  16.38
  17.20
  18.06
  18.96
  19.91
  20.91
  21.95
  23.05
PV of cash for distribution, $m
  -255
  -209
  -201
  -193
  -184
  -175
  -165
  -155
  -144
  -133
  -122
  -111
  -100
  -89
  -78
  -68
  -58
  -49
  -41
  -34
  -27
  -22
  -17
  -13
  -10
  -7
  -5
  -3
  -2
  -2
Current shareholders' claim on cash, %
  50.0
  1.7
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

FINANCIAL RATIOS  of  Immunogen (IMGN)

Valuation Ratios
P/E Ratio -6.4
Price to Sales 23.1
Price to Book -3.3
Price to Tangible Book
Price to Cash Flow -6.1
Price to Free Cash Flow -6
Growth Rates
Sales Growth Rate -63.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -90%
Cap. Spend. - 3 Yr. Gr. Rate -34%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity -63.4%
Total Debt to Equity -63.4%
Interest Coverage 0
Management Effectiveness
Return On Assets -33.1%
Ret/ On Assets - 3 Yr. Avg. -35.8%
Return On Total Capital 385.4%
Ret/ On T. Cap. - 3 Yr. Avg. -101.5%
Return On Equity 67.2%
Return On Equity - 3 Yr. Avg. 191.4%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -345.5%
EBITDA Margin - 3 Yr. Avg. -214.2%
Operating Margin -304.5%
Oper. Margin - 3 Yr. Avg. -191.9%
Pre-Tax Margin -359.1%
Pre-Tax Margin - 3 Yr. Avg. -223.9%
Net Profit Margin -359.1%
Net Profit Margin - 3 Yr. Avg. -223.9%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

IMGN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the IMGN stock intrinsic value calculation we used $115.447 million for the last fiscal year's total revenue generated by Immunogen. The default revenue input number comes from 0001 income statement of Immunogen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our IMGN stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.6%, whose default value for IMGN is calculated based on our internal credit rating of Immunogen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Immunogen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of IMGN stock the variable cost ratio is equal to 308.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for IMGN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 6.2% for Immunogen.

Corporate tax rate of 27% is the nominal tax rate for Immunogen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the IMGN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for IMGN are equal to 16.2%.

Life of production assets of 3.1 years is the average useful life of capital assets used in Immunogen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for IMGN is equal to -40.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-17.895 million for Immunogen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 148.792 million for Immunogen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Immunogen at the current share price and the inputted number of shares is $0.9 billion.

RELATED COMPANIES Price Int.Val. Rating
CTMX CytomX Therape 14.14 12.87  sell
LLY Eli Lilly 112.20 67.15  sell
AMGN Amgen 192.45 130.16  sell
SGEN Seattle Geneti 54.39 1.07  str.sell

COMPANY NEWS

▶ Healthcare Stocks with Turnaround Potential   [Nov-14-18 11:35AM  ACCESSWIRE]
▶ ImmunoGen Waits to Leap "Forward"   [Nov-09-18 02:12PM  Motley Fool]
▶ Here's Why ImmunoGen Closed Almost 12% Up on Wednesday   [Nov-07-18 08:28PM  Motley Fool]
▶ ImmunoGen: 3Q Earnings Snapshot   [08:36AM  Associated Press]
▶ Q3 Earnings Outlook For ImmunoGen   [Nov-01-18 02:55PM  Benzinga]
▶ Here's Why ImmunoGen Fell Today   [Oct-22-18 11:05AM  Motley Fool]
▶ Cancer Companies to Watch   [Oct-15-18 10:30AM  ACCESSWIRE]
▶ Why ImmunoGen Inc. Dropped 8% Today   [Oct-05-18 05:00PM  Motley Fool]
▶ Why ImmunoGen, Inc. Fell 10.6% on Thursday   [Oct-04-18 05:53PM  Motley Fool]
▶ Who Owns Most Of ImmunoGen Inc (NASDAQ:IMGN)?   [Sep-19-18 08:31AM  Simply Wall St.]
▶ ImmunoGen, Inc. to Host Earnings Call   [06:00AM  ACCESSWIRE]
▶ Immunogen Earnings Preview   [Jul-26-18 02:59PM  Benzinga]
▶ Here's Why ImmunoGen Fell 15.1% in June   [Jul-13-18 02:33PM  Motley Fool]
▶ Better Buy: Exelixis, Inc. vs. Immunogen, Inc.   [Jun-26-18 08:05AM  Motley Fool]
▶ Here's Why ImmunoGen Inc. Fell 9.2% Today   [Jun-07-18 05:33PM  Motley Fool]
▶ Why ImmunoGen Jumped Higher Today   [May-31-18 03:31PM  Motley Fool]
▶ ImmunoGen Presses Forward   [May-08-18 07:34PM  Motley Fool]
▶ ImmunoGen (IMGN) Q1 Loss Wider, Revenues Beat   [May-04-18 07:18AM  Zacks]
▶ ImmunoGen: 1Q Earnings Snapshot   [06:40AM  Associated Press]
▶ ImmunoGen, Inc. to Host Earnings Call   [06:00AM  ACCESSWIRE]
▶ Why ImmunoGen, Inc. Stock Is on the Rise Today   [Apr-27-18 01:04PM  Motley Fool]
▶ What Knocked ImmunoGen, Inc. Down 15% on Tuesday?   [Mar-28-18 01:56PM  Motley Fool]
▶ ImmunoGen (IMGN) Jumps: Stock Rises 7%   [Mar-27-18 08:56AM  Zacks]
▶ 3 Biotech Stocks That Soared This Week: Are They Buys?   [Feb-17-18 10:34AM  Motley Fool]
▶ ImmunoGen Moves One Foot Forward   [Feb-13-18 03:54PM  Motley Fool]
▶ Why ImmunoGen Jumped Higher Today   [Feb-12-18 03:50PM  Motley Fool]
▶ ImmunoGen reports 4Q loss   [06:56AM  Associated Press]
▶ Why ImmunoGen Inc. Pulled Back Today   [Feb-05-18 04:40PM  Motley Fool]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.